{"PubmedArticle": [{"MedlineCitation": {"OtherID": [], "SpaceFlightMission": [], "KeywordList": [["microcirculation and inflammation", "ozone therapy", "puffy fingers", "puffy hands", "raynaud\u2019s phenomenon", "systemic scleroderma", "systemic sclerosis", "videocapillaroscopy"]], "CitationSubset": [], "InvestigatorList": [], "OtherAbstract": [], "GeneralNote": [], "PMID": "36440300", "DateRevised": {"Year": "2022", "Month": "11", "Day": "29"}, "Article": {"Language": ["eng"], "ArticleDate": [{"Year": "2022", "Month": "11", "Day": "23"}], "ELocationID": ["e31831", "10.7759/cureus.31831"], "Journal": {"ISSN": "2168-8184", "JournalIssue": {"Volume": "14", "Issue": "11", "PubDate": {"Year": "2022", "Month": "Nov"}}, "Title": "Cureus", "ISOAbbreviation": "Cureus"}, "ArticleTitle": "Rapid and Sustained Effect of Ozone Major Autohemotherapy for Raynaud and Hand Edema in Systemic Sclerosis Patient: A Case Report.", "Pagination": {"StartPage": "e31831", "MedlinePgn": "e31831"}, "Abstract": {"AbstractText": ["Systemic sclerosis (SSc) is a complex disease\u00a0characterized by vascular injury with endothelial cell and platelet activation, immune dysregulation with inflammatory cytokines and fibroblast activation. The Raynaud phenomenon and puffy hands and fingers are common early manifestations of the disease that have a negative impact on patients' quality of life. Vasodilators such as calcium channel blockers, PDE5 inhibitors, and prostacyclin analogs are recommended treatments, but they often have side effects and are not always effective.\u00a0Ozone\u00a0is an oxygen donor, an immunomodulator, an inducer of antioxidant enzymes and the endothelial nitric oxide synthase,\u00a0a metabolic booster, and a stem cell activator.\u00a0I report the case of a scleroderma patient treated effectively with autohemotherapy with ozone and a clear reduction of Raynaud's episodes and resolution of the edema of the hands. Furthermore, the capillaroscopic evaluation showed a rapid modification of the microcirculation which remained unchanged for months. Ozone therapy is effective to treat the Raynaud phenomenon and hand edema and should be considered, at least, as a complementary therapy to the standard of care, especially in patients who are unresponsive or with frequent adverse drug reactions. Further studies will be needed to confirm the efficacy of ozone therapy in scleroderma vasculopathy."], "CopyrightInformation": "Copyright \u00a9 2022, Galluccio et al."}, "AuthorList": [{"Identifier": [], "AffiliationInfo": [{"Identifier": [], "Affiliation": "Rheumatology & Rehabilitation, Fisiotech Lab Studio, Firenze, ITA."}, {"Identifier": [], "Affiliation": "Pain Medicine, Morphological Madrid Research Center (MoMaRC), Madrid, ESP."}], "LastName": "Galluccio", "ForeName": "Felice", "Initials": "F"}], "PublicationTypeList": ["Case Reports"]}, "MedlineJournalInfo": {"Country": "United States", "MedlineTA": "Cureus", "NlmUniqueID": "101596737", "ISSNLinking": "2168-8184"}, "CoiStatement": "The authors have declared that no competing interests exist."}, "PubmedData": {"ReferenceList": [{"Reference": [{"Citation": "Systemic sclerosis. Denton CP, Khanna D. Lancet . 390;1016:140\u20136736.", "ArticleIdList": ["28413064"]}, {"Citation": "Vascular involvement in systemic sclerosis. Kahaleh BM. https://www.clinexprheumatol.org/search.asp?Title=Vascular+involvement+in+systemic+sclerosis+%28SSc%29&a=s Clin Exp Rheumatol. 2004;22:19\u201323.", "ArticleIdList": ["15344592"]}, {"Citation": "Raynaud's phenomenon and the role of capillaroscopy. Cutolo M, Grassi W, Cerinic MM. Arthritis Rheum. 2003;48:3023\u20133030.", "ArticleIdList": ["14613262"]}, {"Citation": "Raynaud's phenomenon-an update on diagnosis, classification and management. Pauling JD, Hughes M, Pope JE. Clin Rheumatol. 2019;38:3317\u20133330.", "ArticleIdList": ["31420815"]}, {"Citation": "Two faces of the same coin: Raynaud phenomenon and digital ulcers in systemic sclerosis. Galluccio F, Matucci-Cerinic M. Autoimmun Rev. 2011;10:241\u2013243.", "ArticleIdList": ["20863907"]}, {"Citation": "The ozone paradox: ozone is a strong oxidant as well as a medical drug. Bocci V, Borrelli E, Travagli V, Zanardi I. Med Res Rev. 2009;29:646\u2013682.", "ArticleIdList": ["19260079"]}, {"Citation": "Ozone: a new therapeutic agent in vascular diseases. Bocci V, Zanardi I, Travagli V. Am J Cardiovasc Drugs. 2011;11:73\u201382.", "ArticleIdList": ["21446774"]}, {"Citation": "Ozone treatment reduces markers of oxidative and endothelial damage in an experimental diabetes model in rats. Al-Dalain SM, Mart\u00ednez G, Candelario-Jalil E, Men\u00e9ndez S, Re L, Giuliani A, Le\u00f3n OS. Pharmacol Res. 2001;44:391\u2013396.", "ArticleIdList": ["11712870"]}, {"Citation": "Non-invasive oxygen-ozone therapy in treating digital ulcers of patients with systemic sclerosis. Hassanien M, Rashad S, Mohamed N, Elawamy A, Ghaly MS. https://pubmed.ncbi.nlm.nih.gov/30414369/ Acta Reumatol Port. 2018;43:210\u2013216.", "ArticleIdList": ["30414369"]}, {"Citation": "Efficacy of local oxygen-ozone therapy for the treatment of digital ulcer refractory to medical therapy in systemic sclerosis: a randomized controlled study. Kaymaz S, Karasu U, Alkan H, et al. Mod Rheumatol. 2022;32:1102\u20131107.", "ArticleIdList": ["34865095"]}, {"Citation": "Update of EULAR recommendations for the treatment of systemic sclerosis. Kowal-Bielecka O, Fransen J, Avouac J, et al. Ann Rheum Dis. 2017;76:1327\u20131339.", "ArticleIdList": ["27941129"]}, {"Citation": "The International Scientific Committee of Ozone Therapy: major autohemotherapy.  [\nNov;\n2022 \n]. 2022. https://isco3.org/wp-content/uploads/2017/03/ISCO3-MET-00-01-MAHT-V1-03102016.pdf https://isco3.org/wp-content/uploads/2017/03/ISCO3-MET-00-01-MAHT-V1-03102016.pdf"}, {"Citation": "Updated review on ozone therapy in pain medicine. Hidalgo-Tall\u00f3n FJ, Torres-Morera LM, Baeza-Noci J, Carrillo-Izquierdo MD, Pinto-Bonilla R. Front Physiol. 2022;13:840623.", "ArticleIdList": ["PMC8904924", "35283802"]}, {"Citation": "Points to consider for skin ulcers in systemic sclerosis. Galluccio F, Allanore Y, Czirjak L, Furst DE, Khanna D, Matucci-Cerinic M. Rheumatology (Oxford) 2017;56:0\u201371.", "ArticleIdList": ["PMC5850787", "28992171"]}], "ReferenceList": []}], "History": [{"Year": "2022", "Month": "11", "Day": "23"}, {"Year": "2022", "Month": "11", "Day": "28", "Hour": "4", "Minute": "52"}, {"Year": "2022", "Month": "11", "Day": "29", "Hour": "6", "Minute": "0"}, {"Year": "2022", "Month": "11", "Day": "29", "Hour": "6", "Minute": "1"}, {"Year": "2022", "Month": "11", "Day": "23"}], "PublicationStatus": "epublish", "ArticleIdList": ["36440300", "PMC9685362", "10.7759/cureus.31831"]}}], "PubmedBookArticle": []}